IMPACT OF SECONDARY TRANSURETHRAL RESECTION ON RECURRENCE RATES IN PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER
https://doi.org/10.17650/1726-9776-2012-8-2-66-71
Abstract
The incidence of recurrences was analyzed in patients with non-muscle-invasive bladder cancer who had undergone primary or secondary transurethral resection (TUR). The 5-year incidence of recurrences was studied. The authors also discuss whether it is reasonable to use second-look (restaging) TUR, which allows this procedure to be recommended for routine clinical practice.
About the Authors
O. A. Khalmurzaev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Department of Urology
Russian Federation
Department of Urology
V. B. Matveev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Department of Urology
Russian Federation
Department of Urology
S. B. Peterson
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Department of Urology
Russian Federation
Department of Urology
V. A. Romanov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Department of Urology
Russian Federation
Department of Urology
A. D. Panakhov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Department of Urology
Russian Federation
Department of Urology
A. V. Khailenko
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Department of Urology
Russian Federation
Department of Urology
References
1. Матвеев Б.П. Клиническая онкоурология. М., 2011.
2. Sylvester R.J., van der Meijden A.P., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466−77.
3. Нerr H., Dalbagni G. Is «second −look» (re-staging) transurethral resection of bladder tumors a new standard of care? Arab J Urol 2011;9:7−10.
4. Herr H.W. A restaging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006; 97:1194−8.
5. Soloway M., Safer M., Vaidya A. Contemporary management of stage Tl transitional cell carcinoma of the bladder. J Urol (Baltimore) 2002;167:1573−83.
6. Babjuk M., Oosterlinck W., Sylvester R. et al. EAU guidelines on nonmuscle- invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303−14.
7. Schips L., Augustin H., Zigeuner R.E. et al. Is repeat transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59:220−3.
8. Grimm M.O. Steinhoff Ch., Simon X. et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003;170 (2 Pt 1): 433−7.
9. Brauers A., Buettner R., Jakse G. Second resection and prognosis in primary high risk superficial bladder cancer. J Urol 2001; 165:808−10.
10. Herr H.W. A restaging transurethral resection of high risk superficial bladder cancer improves the initial response to BCG therapy. J Urol 2005;174:2134−7.
11. Dalbagni G. Bladder cancer: Restaging TUR reduces recurrence and progression risk. Nat Rev Urol 2010;7(12):649−50.
Review
For citations:
Khalmurzaev O.A., Matveev V.B., Peterson S.B., Romanov V.A., Panakhov A.D., Khailenko A.V. IMPACT OF SECONDARY TRANSURETHRAL RESECTION ON RECURRENCE RATES IN PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER. Cancer Urology. 2012;8(2):66-71. (In Russ.) https://doi.org/10.17650/1726-9776-2012-8-2-66-71
Views:
770
Email this article 